A Phase 3 Randomized, Double-blind, Placebo-controlled Study to Evaluate the Safety and Efficacy of MEDI8897, a Monoclonal Antibody With an Extended Half-life Against Respiratory Syncytial Virus, in Healthy Late Preterm and Term Infants (MELODY)

  • Buttery, Jim (Primary Chief Investigator (PCI))

Project: Research

Project Details

Effective start/end date21/01/2020/01/25


  • clinical trial
  • phase 3 study
  • treatment safety
  • Respiratory Syncytial Virus